Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of duvakitug in people with moderately to severely active Ulcerative Colitis UC. This Phase 3, multicenter, randomized, double-blind, placebo-controlled maintenance study aims to understand how well duvakitug works to maintain clinical remission and improve symptoms in participants with UC. The trial is sponsored by Sanofi and includes a large, diverse participant group aged 16 to 80 years. Participants receive subcutaneous injections of either one of three doses of duvakitug or a placebo following the study protocol. The study consists of two main periods a 40-week Pivotal Maintenance Sub-Study and a 240-week Open-Label Extension OLE Sub-Study. Those who do not join the OLE will complete a 45-day follow-up after the maintenance phase. Across both periods, participants may have up to 32 on-site visits to monitor treatment and health status. During the study, participants will undergo various assessments including endoscopy, clinical response evaluations, and symptom scoring by modified Mayo Score. Researchers will monitor clinical remission, endoscopic and histologic improvements, corticosteroid use, fatigue, abdominal pain, quality of life, and hospitalization incidence. Safety will be closely tracked through adverse event reporting and measurement of drug concentration and immune response. The total participation duration can be up to 286 weeks, allowing long-term monitoring of duvakitugs effects.
Actively Recruiting
Researchers are evaluating whether baricitinib can delay the onset of clinical type 1 diabetes T1D in children and adults who are at high risk of developing this condition. This Phase 3, double-blind, randomized, placebo-controlled study includes participants aged 1 to less than 36 years with early-stage type 1 diabetes or specific diabetes-related autoantibodies. The study is sponsored by Eli Lilly and Company and aims to understand if baricitinib can postpone progression to stage 3 T1D. Participants will be randomly assigned to receive either baricitinib or a placebo orally. The intervention period may last up to approximately 5 years, during which the time from baseline to diagnosis of stage 3 type 1 diabetes will be closely monitored. Both groups will be followed to assess changes in glucose metabolism, C-peptide levels, body measurements, and quality of life. During the study, participants will undergo regular assessments including blood tests to measure glucose-stimulated C-peptide, glucose levels, and other metabolic markers at baseline and after one year. Additional evaluations include body height, body mass index percentile, and health surveys. Pharmacokinetics of baricitinib will also be monitored up to week 24. Safety and efficacy data will be collected throughout the study period, lasting up to approximately 5 years per participant.
Actively Recruiting
Researchers are evaluating empasiprubart for adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition causing nerve inflammation and muscle weakness. This Phase 3 randomized, double-blinded, placebo-controlled study aims to demonstrate the efficacy and safety of empasiprubart in treating CIDP. The study is sponsored by argenx and includes adults diagnosed with typical or variant forms of CIDP who have active disease and residual disability. Participants are randomly assigned in part A to receive either empasiprubart or a placebo by intravenous infusion for 24 weeks 6 months. After part A, all participants enter part B, where everyone receives empasiprubart for 96 weeks 24 months. Participants who received empasiprubart in part A will receive a placebo infusion once during part B to maintain blinding. Throughout the study, participants will undergo regular assessments including the adjusted Inflammatory Neuropathy Cause and Treatment aINCAT score, grip strength measurements, muscle strength evaluations, and quality of life questionnaires. Researchers will monitor changes from baseline in motor function, disability, and symptom severity up to 24 weeks in part A and continue evaluations through part B. Safety measures include tracking adverse events and immune responses. The total participation duration can last up to 120 weeks approximately 30 months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
Researchers are studying whether the medicine nerandomilast can help slow lung changes in people aged 40 or older who have a family history of pulmonary fibrosis. This condition causes scarring in the lungs, making breathing difficult, and early lung changes detected by scans may lead to this scarring. The study aims to find ways to prevent lung fibrosis from getting worse in those at higher risk due to family history. Participants are randomly assigned to two groups one takes nerandomilast tablets and the other takes placebo tablets that look the same but contain no medicine. They take one tablet twice daily for about 2 to 3 years. The chance of receiving nerandomilast is 3 in 5. The study includes frequent visits during the first 2 years, approximately every 3 months, then visits every 6 months in the third year, along with phone calls every 3 months during that last year. During the study, doctors regularly check lung function and perform chest scans to monitor lung changes and see if nerandomilast affects the condition. They also track participants health and any side effects. The main measure is the time until lung changes worsen over the full trial period. The total participation time is about 2 to 3 years with ongoing assessments throughout.
Actively Recruiting
Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.
Actively Recruiting
Crohns disease is a chronic inflammatory condition affecting the digestive tract and is currently incurable. This research aims to evaluate how safe and effective the drug upadacitinib is for treating moderately to severely active Crohns disease in real-world settings. The study will monitor any adverse events and track changes in disease activity among participants. All participants will receive upadacitinib as prescribed by their own doctors according to approved local guidelines. The study plans to enroll about 240 participants in Japan who have recently started upadacitinib treatment. Treatment will follow routine clinical practice without altering the prescribed approach. Participants will be followed for up to 64 weeks with visits that may occur in person or virtually, aligned with standard care. Researchers will assess outcomes such as the percentage of participants experiencing serious infections related to the drug. There is expected to be no extra burden beyond usual medical care throughout the study period.
Actively Recruiting
Researchers are evaluating a new type of dental implant called a periodontal ligament-integrated implant for adults aged 18 and older who need a single-rooted tooth extracted. This exploratory study aims to assess whether this implant can successfully integrate with the jawbone 24 weeks after placement and if it can restore natural tooth functions such as mobility and sensory feedback while maintaining periodontal health. The implant uses residual periodontal ligament tissue in the extraction socket to promote functional attachment, differing from traditional implants that rely solely on bone integration. Participants will undergo extraction of one single-rooted tooth followed immediately by placement of the investigational implant stabilized with a temporary fixation device. This fixation remains for about nine weeks to allow healing and integration. Afterward, a superstructure is placed for controlled chewing load, and the fixation device is removed once stable integration is confirmed. The study involves multiple follow-up visits over 48 weeks, with ongoing oral care and monitoring. During the study, participants will have dental X-rays, CT scans, and clinical exams to evaluate bone healing, periodontal ligament formation, implant stability, and tooth mobility. Researchers will also measure periodontal pocket depth, pain levels, and assess patient quality of life using oral health questionnaires. Safety and implant performance will be closely monitored, with assessments continuing up to 48 weeks to gather comprehensive data on the implants biological feasibility, mechanical behavior, and clinical safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a new oral cladribine formulation in adults with Generalized Myasthenia Gravis gMG. This Phase 3 clinical trial compares two doses of cladribine with a placebo and also studies the long-term safety, sustained effects, and need for retreatment of cladribine in people with gMG. Additionally, the study will examine how the body processes cladribine through a pharmacokinetic sub-study. Participants are randomly assigned to one of three groups placebo, low dose cladribine, or high dose cladribine. Each group receives two separate treatment courses orally, starting on Day 1 and again at Week 5 during the double-blind placebo-controlled period. After this, participants enter a blinded extension where those initially on placebo switch to cladribine doses, and those initially on cladribine receive placebo courses. If needed, participants may enter a retreatment period to receive additional cladribine or placebo doses based on clinical judgment. During the study, participants undergo regular assessments including changes in muscle weakness and daily living activities using specific scales like the MG-ADL. Safety is monitored through tracking adverse events, lab tests, vital signs, and heart monitoring. The study also includes in-depth interviews with a subset of participants to understand their treatment and study experience. The total study duration extends up to 144 weeks, allowing long-term follow-up and evaluation.
Actively Recruiting
Researchers are conducting a Phase 3, randomized, open-label study comparing two ways of giving the drug frexalimabby subcutaneous under the skin injection every 4 weeks versus intravenous IV infusion every 4 weeksin adults aged 18 to 60 years with relapsing multiple sclerosis RMS or non-relapsing secondary progressive multiple sclerosis nrSPMS. The study aims to evaluate the pharmacokinetics, safety, and efficacy of these two administration methods in this population. Participants will receive frexalimab either through an IV infusion or by subcutaneous injection using an on-body delivery system OBDS, with the option for home self-administration starting after appropriate training in Part B of the study. The treatment period for Parts A and B combined lasts 48 weeks 12 months, with an optional Part C continuing until a long-term safety study begins. Scheduled visits occur monthly between weeks 4 and 24, then every 1 to 3 months in Part B, and every 6 months in Part C. Participants discontinuing treatment early will have additional follow-up visits. During the study, participants will undergo regular on-site visits for drug administration and monitoring. Researchers will collect blood samples to assess drug levels and immune responses, perform MRI scans to track brain lesions, and monitor safety through adverse event reporting and laboratory tests. The studys main outcomes include drug concentration measurements up to week 24 and safety and efficacy assessments up to week 96. Follow-up after treatment ends will continue for 6 months to observe any ongoing effects.
1-10 of 12
1